CYBB and endothelial dysfunction: Although GKT137831, a NOX 1 and 4 inhibitor, did not improve EDR, GSK2795039, a NOX 2 inhibitor, ameliorated endothelial dysfunction in the WTD-GS (+) group (Figs 4, S4E, S4F, S5E and S5F) (P < 0.001), suggesting that NOX2 was involved in endothelial dysfunction in this group.